Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Movement Disorders

• Publication date

  2001-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mds.1091PMID 11391735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• L‐DOPA Does Not Enhance Hydroxyl Radical Formation in the Nigrostriatal Dopamine System of Rats with a Unilateral 6‐Hydroxydopamine Lesion

  2000cited by this paper
• Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

  1998cited by this paper
• Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivo

  1998cited by this paper
• Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.

  1997cited by this paper
• Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice.

  1996cited by this paper
• Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease.

  1996cited by this paper
• 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat

  1996cited by this paper
• l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress

  1996cited by this paper
• Effect of p-chlorophenylalanine at moderate dosage on 5-HT and 5-HIAA concentrations in brain regions of control and p-chloroamphetamine treated rats.

  1996cited by this paper
• Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

  1996cited by this paper
• Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine.

  1996cited by this paper
• Glia conditioned medium protects fetal rat midbrain neurones in culture from L‐DOPA toxicity

  1996cited by this paper
• 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death.

  1995cited by this paper
• Nigral dopaminergic cell loss in vitamin E deficient rats.

  1994cited by this paper
• Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine.

  1994cited by this paper
• Intense oxidative DNA damage promoted by l‐DOPA and its metabolites implications for neurodegenerative disease

  1994cited by this paper
• L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

  1994cited by this paper
• Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid

  1993cited by this paper
• Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.

  1993cited by this paper
• Iron induces degeneration of nigrostriatal neurons.

  1992cited by this paper
• Neurotoxicity of levodopa on catecholamine‐rich neurons

  1992cited by this paper
• Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum

  1992cited by this paper
• The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography.

  1991cited by this paper
• Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.

  1991cited by this paper
• Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease

  1988cited by this paper
• Increased nigral iron content in postmortem parkinsonian brain.

  1987cited by this paper
• Factors that influence the occurrence of response variations in Parkinson's disease

  1987cited by this paper
• Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period

  1986cited by this paper
• Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse

  1981cited by this paper
• Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy

  1979cited by this paper
• Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

  1978cited by this paper

• Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.

  2024cites this paper
• New opportunities for antioxidants in amelioration of neurodegenerative diseases.

  2024cites this paper
• Cannabidiol alleviates the damage to dopaminergic neurons in MPTP-induced Parkinson's disease mice via regulating neuronal apoptosis and neuroinflammation.

  2022cites this paper
• Aberrant Dopamine Homeostasis as a Focal Point in the Mechanism of Environmental Contaminant-Induced Dopaminergic Dysfunction

  2022cites this paper
• iPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

  2022cites this paper
• Disease modification trials in parkinsons disease: A Review Disease modification trials in parkinsons disease: A Review

  2020cites this paper
• Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

  2020cites this paper
• Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.

  2020cites this paper
• Intracerebroventricular administration of dopamine in Parkinson's disease: treatment of motor fluctuations and dyskinesia

  2020cites this paper
• GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology

  2020cites this paper
• Small dose of L-dopa/Benserazide Hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.

  2020cites this paper
• Levodopa treatment in Parkinson's disease: earlier or later?

  2019cites this paper
• Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less

  2019cites this paper
• L‐DOPA for Parkinson's disease—a bittersweet pill

  2018cites this paper
• Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and l-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson’s disease

  2018cites this paper
• Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function

  2018cites this paper
• Dyskinesias and levodopa therapy: why wait?

  2018cites this paper
• Continuous cerebroventricular administration of dopamine : A new treatment for severe dyskinesia in Parkinson ' s disease ?

  2017cites this paper
• Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?

  2017cites this paper
• Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.

  2017cites this paper
• Dissecting the Genetic Basis of Parkinson Disease, Dystonia and Chorea

  2016cites this paper
• Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.

  2016cites this paper
• GTP cyclohydrolase 1 mutations and Parkinson's disease: New insights beyond DOPA‐responsive dystonia

  2015cites this paper
• Levodopa: Effect on cell death and the natural history of Parkinson's disease

  2015cites this paper
• BLOCKING RECEPTOR PROTEIN TYROSINE PHOSPHATASEβ/ζ: A POTENTIAL THERAPEUTIC STRATEGY FOR PARKINSON ́S DISEASE. Running header: RPTPβ/ζ in Parkinson ́s disease

  2015cites this paper
• In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats.

  2015cites this paper
• Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.

  2014cites this paper
• Cannabis resin extract in Parkinson's disease: Behavioral, Neurochemical, and Histological Evaluation

  2014cites this paper
• Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers

  2014cites this paper
• Wykładniki ciśnienia tętniczego w chorobach zwyrodnieniowych układu nerwowego

  2014cites this paper
• Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.

  2014cites this paper
• Investigating group III metabotropic glutamate receptors as novel therapeutic targets in Parkinson's disease and Levodopa-induced dyskinesia

  2014influential citation
• Hydrogen Sulfide: A New Tool to Design and Develop Drugs

  2014cites this paper
• Bases farmacológicas y moleculares de las disquinesias inducidas por L-dopa en un modelo experimental de la enfermedad de Parkinson

  2014cites this paper
• Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

  2013cites this paper
• Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry

  2013cites this paper
• Dampening of Serotonergic System through 5HT1A Receptors is a Promising Target for Treatment of Levodopa Induced Motor Problems.

  2013cites this paper
• L-DOPA- and graft-induced dyskinesia following transplantation.

  2012cites this paper
• Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions.

  2012cites this paper
• Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects.

  2012cites this paper
• Covalent modification and inhibition of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, an endogenously produced neurotoxin relevant to Parkinson's disease

  2012cites this paper
• Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

  2012cites this paper
• Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

  2011cites this paper
• Connecting Parkinson's disease and drug addiction: common players reveal unexpected disease connections and novel therapeutic approaches.

  2011cites this paper
• L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

  2011cites this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cites this paper
• Dopamine Receptors and the Treatment of Parkinson's Disease

  2010cites this paper
• The chemical synthesis, pharmaceutical preparation and toxicity analysis of fluorodopa for positron emission tomography (PET) brain imaging in South Africa

  2010cites this paper
• [Levodopa: from a discovery to new elaborations].

  2010cites this paper
• Striatal Dopaminergic Fiber Recovery After Acute l-DOPA Treatment in 6-Hydroxydopamine (6-OHDA) Lesioned Rats

  2010influential citation
• EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP

  2010cites this paper
• Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

  2010cites this paper
• Neuroprotective effect of l‐dopa on dopaminergic neurons is comparable to pramipexol in MPTP‐treated animal model of Parkinson’s disease: a direct comparison study

  2009cites this paper
• Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson’s disease

  2009cites this paper
• UNIVERSITY OF FLORIDA THESIS OR DISSERTATION FORMATTING TEMPLATE

  2009cites this paper
• Blocking receptor protein tyrosine phosphatase beta/zeta: a potential therapeutic strategy for Parkinson's disease.

  2009cites this paper
• Targets for neuroprotection in Parkinson's disease.

  2009cites this paper
• Long-term effects of irradiation with iron-56 particles on the nigrostriatal dopamine system

  2009cites this paper
• Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model

  2008cites this paper
• Pleiotrophin receptor RPTP‐ζ/β expression is up‐regulated by l‐DOPA in striatal medium spiny neurons of parkinsonian rats

  2008cites this paper
• The Role of 3-O-Methyldopa in the Side Effects of l-dopa

  2008cites this paper
• Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.

  2008cites this paper
• BEATING A DEAD HORSE: DOPAMINE AND PARKINSON DISEASE

  2007cites this paper
• Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition

  2007cites this paper
• Beating a dead horse

  2007cites this paper
• The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models

  2007cites this paper
• Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa

  2007cites this paper
• When Should Levodopa Therapy be Initiated in Patients with Parkinson’s Disease?

  2007cites this paper
• Short-Term Supplementation with Plant Extracts Rich in Flavonoids Protect Nigrostriatal Dopaminergic Neurons in a Rat Model of Parkinson's Disease

  2007cites this paper
• Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

  2007cites this paper
• Neuroprotection by taurine and taurine analogues.

  2006cites this paper
• PAPEL DE LA PROTEÍNA PARKINA EN LA FUNCIÓN CELULAR DE LAS NEURONAS DOPAMINÉRGICAS. SUSCEPTIBILIDAD A LA MUERTE CELULAR

  2006cites this paper
• Clinical trials aimed at detecting neuroprotection in Parkinson’s disease

  2006cites this paper
• Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats

  2006cites this paper
• Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.

  2006cites this paper
• SHORT COMMUNICATION Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease

  2005cites this paper
• Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease

  2005cites this paper
• Neuroprotective effects of metabotropic glutamate receptor ligands in a 6‐hydroxydopamine rodent model of Parkinson's disease

  2005cites this paper
• Oxidative stress, antioxidants and neurodegenerative diseases.

  2005cites this paper
• Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease

  2005cites this paper
• Differential effects of l‐DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal‐enriched cultures from parkin knockout and wild‐type mice

  2005cites this paper
• Dopamine Agonist Pergolide Prevents Levodopa-Induced Quinoprotein Formation in Parkinsonian Striatum and Shows Quenching Effects on Dopamine-Semiquinone Generated in Vitro

  2005cites this paper
• Rivastigmine for dementia associated with Parkinson’s disease

  2005cites this paper
• Prospects for Slowing the Progression of Parkinson's Disease

  2005cites this paper
• Semi‐chronic increase in striatal level of 3,4‐dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones

  2004cites this paper
• Levodopa in the treatment of Parkinson's disease: Current controversies

  2004cites this paper
• Is levodopa toxic?

  2004cites this paper
• Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system

  2004cites this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cites this paper
• Estrogen interacts with the IGF‐1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6‐hydroxdopamine lesions

  2004cites this paper
• Recherche d’une toxicité du 3,4-dihydroxyphénylacétaldéhyde (DOPAL) in vitro et in vivo

  2004cites this paper
• The antioxidant drink “effective microorganism‐X (EM‐X)” pre‐treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6‐hydroxydopamine‐lesion rat model of Parkinson's disease

  2004cites this paper
• Levodopa and the progression of Parkinson's disease.

  2004cites this paper
• [Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)].

  2004cites this paper
• New developments in levodopa therapy

  2004cites this paper
• Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress

  2003cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1236 Pharmacotherapy for Parkinson's Disease - Observations and Innovations

  2003cites this paper
• Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.

  2003cites this paper
• Initial agonist treatment of Parkinson disease

  2003cites this paper
• Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

  2003cites this paper